BofA raised the firm’s price target on Arrowhead (ARWR) to $62 from $42 and keeps a Buy rating on the shares. Following fiscal Q4 results, the firm increased its price target to reflect clinical execution of Arrowhead’s obesity and partnered neuromuscular programs ahead of initial Phase 1/2 readouts, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR: